Literature DB >> 4087306

Effect of creatine phosphate administration on the rat heart adenylate pool.

S Ronca-Testoni, P Galbani, G Ronca.   

Abstract

Creatine phosphate (CP) has been shown to possess some pharmacological properties. When added to cardioplegic solutions it improves their myocardial protection. Furthermore exogenous creatine phosphate shows an anti-arrhythmic effect in the experimental animal and appears to decrease lactate formation following haemorrhagic shock. These properties have been ascribed to the conservation of the tissue stores of ATP. Recently Down et al. have observed higher rat heart levels of ATP and creatine phosphate after the intravenous administration of creatine phosphate. Since it is difficult to find the conditions for an increase of the adenylate pool, it seems of interest to establish whether the ATP increase is due to a rise of the total adenylate pool or of the energy charge or of both. Similarly the higher creatine phosphate concentration may be ascribed to a variation of the CP/creatine ratio or to an increase in the creatine plus CP pool. In the present paper we report that the administration of creatine phosphate raises both the adenylate pool and the energy charge. An increase of creatine and the creatine phosphate pool was also observed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4087306     DOI: 10.1016/s0022-2828(85)80114-0

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  2 in total

1.  Electrophysiologic and inotropic effects of O-benzyl-phosphocreatine in rabbit myocardium.

Authors:  W Tuganowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

2.  A stability-Indicating HPLC Method for Simultaneous Determination of Creatine Phosphate Sodium and its Related Substances in Pharmaceutical Formulation.

Authors:  Zengkun Xie; Lihua Wei; Qin Yang; Min Yang; Hongchun Pan; Hong Liu
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.